Company intelligence / Profile preview

Sparkag

Philadelphia, Pennsylvania, United Statessparkag.com.br ↗

Ownership: Private
Development stage: Other

Overview

Spark developed Luxturna, the first FDA-approved in vivo gene therapy for an inherited retinal disorder. Its pipeline includes approved and investigational therapies targeting rare genetic diseases. Some programs have faced clinical setbacks or discontinuation; Luxturna sales declined significantly in 2024. The company remains focused on eye, liver, neurodegenerative diseases, immune system disorders, and enabling technologies for optimized delivery

Therapeutic areas: Rare DiseasesOphthalmologyHematologyNeurology
Modalities: Gene therapyAdeno-associated viral vector (AAV) gene therapy
Industry: Biotech

Partnerships

Pfizer (co-development of fidanacogene elaparvovec/SPK‑9001)

Beyond the preview

Go deeper on Sparkag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sparkag.

Explore the full profile